BioCentury
ARTICLE | Company News

CV Therapeutics sales and marketing update

March 20, 2006 8:00 AM UTC

CVTX began shipping its Ranexa ranolazine to U.S. wholesalers. The selective late sodium current blocker is approved to treat chronic angina. ...